Microbiome Drug Development
Online Symposium
24 September 2024 | Online, BST (UTC+1)
Bringing together key opinion leaders from across the globe for focused discussions on microbiome discovery & therapeutic development
Sponsored By
Sengenics Corporation LLC, a functional proteomics company, is committed to advancing precision medicine by empowering researchers with biologically relevant and actionable immunoproteomic insights across a broad spectrum of diseases. At the heart of its mission, Sengenics offers advanced, high-throughput tools using proprietary technology to precisely detect autoantibody biomarkers and protein interactions for basic, translational, and clinical research. Its robust tools have been leveraged by top pharmaceutical companies and leading research institutions to enhance disease understanding and streamline the biomarker pipeline. Sengenics is headquartered in the U.S. and has a worldwide network of offices, distributors, and service providers.
Key Topics Covered
- Identification and characterization of bacterial species associated with different disease areas & responses to therapeutics
- Application of antibody profiling in microbiota-influenced diseases
- Human microbiome analysis & microbiome profiling:
» NGS methods
» Single- cell genomics - Data driven approaches to microbiome discovery: AI/ML; advanced bioinformatics tools and technologies
- Therapeutics development case studies:
» Kidney Diseases
» Cancer & autoimmune diseases - Standardisation of manufacturing processes
Benefits of Attending
- Meet with global key innovators in microbiome drug development. This highly-focused online symposium will bring together thought leaders attendees from pharma & biotech companies and academic institutions. 2024 attendees include: Chief Technology Officer, Adiso Therapeutics; Microbiome Group Leader, MHRA and Professor, University of Florence
- Hear about the latest developments in microbiome discovery. This highly anticipated event brings together key opinion leaders to discuss novel technologies, human microbiome analysis & microbiome profiling techniques and data-driven approaches to microbiome discovery such as AI/ML
- Discuss the latest advancements in microbiome-based therapeutic development. Learn about exploring the development of live bacterial therapies, targeting & modulating the microbiome for therapeutics purposes and hear case studies from various therapeutic areas
- Followed by the release of the ‘Harnessing Microbiome Drug Discovery & Development report detailing key insights, methodologies, and emerging trends discussed during the event for leveraging microbiome drug development effectively
Latest Resources
GHR Foundation Commits $15m to C2N Diagnostics for Tau Tangle Pathology Test for Diagnosing, Staging Alzheimer’s Disease
GHR’s total investment in C2N has now broken $50 million since 2020.
Study Analyses Predictive Biomarkers for COVID-19 ICU Patient Mortality
The study from the Federal University of Paraíba, Brazil analyses a series of haematological, biochemical, and inflammatory factors all contribute to the mortality of COVID-19 patients in the ICU.
Group Identify Prognostic Biomarker for SCLC and Treatment Using Chemotherapy
SCLC patients that express the gene PCDHB4 have a higher likelihood of developing a resistance to chemotherapy.
Proteomic Analysis of Serum Extracellular Vesicles Reveals Potential Biomarkers for Neuroblastoma
The proteomic analysis of extracellular vesicles is shaping up to be a promising biomarker discovery technique for diseases like neuroblastoma.
Blood Biomarkers Signal Increased Risk of Alzheimer's & MND After Multiple Rugby Concussions
Results that show rugby players that have sustained multiple concussions present with markers of neurodegenerative disease development.
Life Science Players Join €23m European Project for Precision Medicine, PRECISEU
The project will bring together life science institutions across European nations in the interest of expanding development of and access to advanced therapy medicinal products.
Meet Our Expert Speakers
Microbiome Drug Development Online Symposium again brings together a panel of prominent leaders and scientists, sharing new case studies, innovative, data and industry outlooks.
Confirmed speakers include:
Amedeo Amedei
Full Professor,
University of Florence
Bharat Dixit
Chief Technology Officer,
Adiso Therapeutics
Chrysi Sergaki
Group Leader,
MHRA
Lesley Hoyles
Professor of Microbiome and Systems Biology,
Nottingham Trent University
Mona Bajaj - Elliott
Associate Professor,
University College London
Register Your Interest
Submit your details and a member of our team will be in touch